Who has been buying Aprogen Biologics stock?

1 distinct insiders have filed 1 disclosed insider purchases in Aprogen Biologics (003060), most recently on 2026-05-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Aprogen Biologics have?

Aprogen Biologics has 1 buy-side and 0 sell-side disclosures on record, covering ₩164M ($114K) in total reported value, spanning 2024-03-12 to 2026-05-29.

Where does StockDrifts get Aprogen Biologics insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Aprogen Biologics 003060

Company

에이프로젠바이오로직스Aprogen Biologics

Insiders

Buys

Total Value

₩164M ($114K)

Avg Return

-73.15%

Last Filing

2026-05-29

Aprogen Biologics (003060) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩164M ($114K) in reported transaction value. The earliest filing StockDrifts holds for Aprogen Biologics is dated 2024-03-12; the most recent is 2026-05-29. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -73.15%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-28	BUY	행사가액조정	에이프로젠 Aprogen	-	15.9K	₩2,045	+3.7%	₩32M ($23K)
2026-07-28	BUY	제3자배정유상증자	에이프로젠 Aprogen	-	1.1M	₩2,045	+3.7%	₩2.0B ($1.4M)
2026-05-29	BUY	CB인수	에이프로젠 Aprogen	-	2.3M	₩3,165	-15.2%	₩7.1B ($5.0M)
2026-04-28	BUY	유상신주취득	에이프로젠 Aprogen	-	592.6K	₩251	+0.0%	₩149M ($103K)
2026-04-16	SELL	주식병합	지베이스 Gbase	-	-47	₩251	-1531.5%	₩12K ($8)
2026-04-15	SELL	자본감소	김용우 Yongwoo Kim	Managing Director	-2.2K	₩251	-1531.5%	₩551K ($383)
2026-04-15	SELL	자본감소	나오성 Naoseong	Managing Director	-12.2K	₩251	-1531.5%	₩3M ($2K)
2026-04-15	SELL	자본감소	에이프로젠 Aprogen	-	-105.3M	₩251	+0.0%	₩26.4B ($18.4M)
2026-04-15	SELL	자본감소	김정출 Kim Jeong-chul	CEO	-20.4K	₩251	-1531.5%	₩5M ($4K)
2026-04-15	SELL	자본감소	강성호 Seongho Kang	Internal director	-11.5K	₩251	-1531.5%	₩3M ($2K)
2026-04-15	SELL	자본감소	김안수 Ansu Kim	Managing Director	-4.5K	₩251	-1531.5%	₩1M ($783)
2025-05-07	SELL	장외매도	에이프로젠 Aprogen	-	-55.3M	₩682	+45.6%	₩37.7B ($26.2M)
2025-04-19	SELL	행사가액조정	에이프로젠 Aprogen	-	-775.9K	₩726	+48.9%	₩563M ($391K)
2025-01-19	BUY	행사가액조정	에이프로젠 Aprogen	-	11.7M	₩770	-51.8%	₩9.0B ($6.3M)
2024-10-21	BUY	행사가액조정	에이프로젠 Aprogen	-	6.3M	₩888	-58.2%	₩5.6B ($3.9M)
2024-08-20	SELL	장외매도	에이프로젠 Aprogen	-	-10.5M	₩1,016	+63.5%	₩10.7B ($7.4M)
2024-08-13	BUY	제3자배정유상증자	에이프로젠 Aprogen	-	33.0M	₩1,023	-63.7%	₩33.8B ($23.5M)
2024-08-06	SELL	기타	에이프로젠 Aprogen	-	-6.5M	₩1,013	+63.4%	₩6.6B ($4.6M)
2024-08-02	BUY	제3자배정유상증자	에이프로젠 Aprogen	-	33.0M	₩1,073	-65.4%	₩35.5B ($24.6M)
2024-07-23	SELL	기타	에이프로젠 Aprogen	-	-13.0M	₩1,219	+69.6%	₩15.9B ($11.0M)
2024-07-22	SELL	장외매도	에이프로젠 Aprogen	-	-8.8M	₩1,229	+69.8%	₩10.8B ($7.5M)
2024-07-19	BUY	CB인수	에이프로젠 Aprogen	-	38.1M	₩1,335	-72.2%	₩50.9B ($35.4M)
2024-06-28	BUY	PROGRAM	배윤경 Bae Yun-kyung	Managing Director	1.2K	₩1,005	-63.1%	₩1M ($863)
2024-06-28	SELL	기타	김정출 Kim Jeong-chul	CEO	-21.9K	₩1,005	+63.1%	₩22M ($15K)
2024-06-28	SELL	기타	에이프로젠 Aprogen	-	-21.5M	₩1,005	+63.1%	₩21.6B ($15.0M)
2024-06-28	SELL	기타	배윤경 Bae Yun-kyung	Managing Director	-1.0K	₩1,005	+63.1%	₩1M ($719)
2024-06-28	SELL	기타	김안수 Ansu Kim	Managing Director	-2.2K	₩1,005	+63.1%	₩2M ($2K)
2024-06-28	SELL	기타	김용우 Yongwoo Kim	moving	-1.1K	₩1,005	+63.1%	₩1M ($747)
2024-06-28	SELL	기타	강성호 Seongho Kang	Managing Director	-6.2K	₩1,005	+63.1%	₩6M ($4K)
2024-06-28	SELL	기타	나오성 Naoseong	Managing Director	-11.8K	₩1,005	+63.1%	₩12M ($8K)
2024-06-28	SELL	기타	강종수 Jongsu Kang	Internal director	-3.3K	₩1,005	+63.1%	₩3M ($2K)
2024-06-28	BUY	PROGRAM	에이프로젠 Aprogen	-	21.5M	₩1,005	-63.1%	₩21.6B ($15.0M)
2024-06-28	BUY	PROGRAM	에이프로젠 Aprogen	-	8.8M	₩1,005	-63.1%	₩8.9B ($6.2M)
2024-06-28	BUY	PROGRAM	에이프로젠 Aprogen	-	2.4M	₩1,005	-63.1%	₩2.4B ($1.7M)
2024-06-28	BUY	PROGRAM	김안수 Ansu Kim	Managing Director	2.6K	₩1,005	-63.1%	₩3M ($2K)
2024-06-28	BUY	PROGRAM	김용우 Yongwoo Kim	moving	1.3K	₩1,005	-63.1%	₩1M ($895)
2024-06-28	BUY	PROGRAM	강성호 Seongho Kang	Managing Director	6.2K	₩1,005	-63.1%	₩6M ($4K)
2024-06-28	BUY	PROGRAM	나오성 Naoseong	Managing Director	1.2K	₩1,005	-63.1%	₩1M ($824)
2024-06-28	BUY	PROGRAM	강종수 Jongsu Kang	Internal director	3.9K	₩1,005	-63.1%	₩4M ($3K)
2024-06-03	SELL	장외매도	에이프로젠 Aprogen	-	-14.3M	₩1,140	+67.5%	₩16.3B ($11.3M)
2024-05-24	BUY	PROGRAM	강종수 Jongsu Kang	Internal director	3.3K	₩1,300	-71.5%	₩4M ($3K)
2024-05-24	BUY	PROGRAM	강성호 Seongho Kang	Managing Director	6.2K	₩1,300	-71.5%	₩8M ($6K)
2024-05-24	BUY	PROGRAM	김안수 Ansu Kim	Managing Director	2.2K	₩1,300	-71.5%	₩3M ($2K)
2024-05-24	BUY	PROGRAM	김용우 Yongwoo Kim	moving	1.1K	₩1,300	-71.5%	₩1M ($966)
2024-05-24	BUY	PROGRAM	배윤경 Bae Yun-kyung	Managing Director	1.0K	₩1,300	-71.5%	₩1M ($930)
2024-05-24	BUY	PROGRAM	나오성 Naoseong	Managing Director	11.8K	₩1,300	-71.5%	₩15M ($11K)
2024-05-24	BUY	PROGRAM	김정출 Kim Jeong-chul	CEO	21.9K	₩1,300	-71.5%	₩28M ($20K)
2024-05-24	BUY	PROGRAM	에이프로젠 Aprogen	-	35.8M	₩1,300	-71.5%	₩46.5B ($32.3M)
2024-04-24	BUY	행사가액조정	에이프로젠 Aprogen	-	1.7M	₩1,259	-70.5%	₩2.2B ($1.5M)
2024-04-14	BUY	행사가액조정	에이프로젠 Aprogen	-	3.4M	₩1,427	-74.0%	₩4.9B ($3.4M)

Showing the 50 most recent of 60 filings.

Frequently asked questions

Who has been buying Aprogen Biologics stock?: 1 distinct insiders have filed 1 disclosed insider purchases in Aprogen Biologics (003060), most recently on 2026-05-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Aprogen Biologics have?: Aprogen Biologics has 1 buy-side and 0 sell-side disclosures on record, covering ₩164M ($114K) in total reported value, spanning 2024-03-12 to 2026-05-29.
Where does StockDrifts get Aprogen Biologics insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Aprogen Biologics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.